CN112656915A - Composition for inhibiting prostatic hyperplasia - Google Patents
Composition for inhibiting prostatic hyperplasia Download PDFInfo
- Publication number
- CN112656915A CN112656915A CN202011595868.2A CN202011595868A CN112656915A CN 112656915 A CN112656915 A CN 112656915A CN 202011595868 A CN202011595868 A CN 202011595868A CN 112656915 A CN112656915 A CN 112656915A
- Authority
- CN
- China
- Prior art keywords
- prostatic hyperplasia
- inhibiting
- composition
- parts
- lycopene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Abstract
The invention discloses a composition for inhibiting prostatic hyperplasia, which belongs to the field of health food, and is prepared by compounding turmeric, lycopene and mixed tocopherol, so that the prostatic hyperplasia can be effectively inhibited through the synergistic interaction of the components, and the effect is better than that of the turmeric and the lycopene which are used independently. In addition, the composition for inhibiting the prostatic hyperplasia has high safety and no toxic or side effect. The invention also provides a preparation method of the composition for inhibiting the prostatic hyperplasia, and the preparation method has simple preparation process and can be used for industrial mass production. The invention also provides application of the composition for inhibiting the prostatic hyperplasia in preparation of a product for inhibiting the prostatic hyperplasia.
Description
Technical Field
The invention relates to the field of medical health foods, in particular to a composition for inhibiting prostatic hyperplasia.
Background
Benign prostatic hyperplasia is a common middle-aged and old-aged male disease, is manifested by symptoms of frequent micturition, urgent micturition, unsmooth urination, increased nocturia, urinary retention and the like, may cause complications such as urinary tract infection, vesical calculus and the like, and even may cause renal function injury. The pathogenesis of prostatic hyperplasia is a very complex pathological process involving a plurality of factors, such as hormones, endocrine, growth factors, inflammatory factors, etc., and the pathogenesis of prostatic hyperplasia can be the result of the single dominant action of one of the factors or the combined action of the factors.
At present, the main methods for preventing and treating the prostatic hyperplasia diseases mainly carry out medicament treatment besides physical treatment and surgical treatment, and western medicaments such as antibiotics are mainly used for preventing and treating the prostatic hyperplasia diseases in the medicaments, so that the recurrence rate is high and certain side effects are caused.
It has been found that some plants contain active ingredients that have some effect on prostate disorders. Research on Chenzhi strong team of urology scientific research institute of the first subsidiary hospital of Guangxi medical university finds that curcumin has an induction effect on apoptosis of human prostatic hyperplasia interstitial cells, and the turmeric extract is proved to have a good effect of treating benign prostatic hyperplasia. On the other hand, researches of Leyize and the like in southern medical university affiliated Jinling hospital/eastern war zone general hospital find that the lycopene has good curative effect on treating prostatic hyperplasia combined with lower urinary tract symptoms, and the life quality is obviously improved. Overseas, a randomized, double-blind, placebo-controlled clinical trial study designed by SCHWARZ et al indicates that supplementation with a certain amount of lycopene may achieve an anti-prostatic hyperplasia effect, and that lycopene may reduce the PSA level in patients with benign prostatic hyperplasia, which may exert certain efficacy in the prevention of prostate cancer.
However, there is no corresponding literature or report on the combination of these substances to develop or prepare a product for inhibiting prostatic hyperplasia, nor is there any relevant research to demonstrate whether the substances or other components have synergistic effects.
Disclosure of Invention
Based on the shortcomings of the prior art, the invention aims to provide a composition for inhibiting prostatic hyperplasia.
In order to achieve the purpose, the invention adopts the technical scheme that:
a composition for inhibiting prostatic hyperplasia comprises the following components: turmeric, mixed tocopherols, and lycopene.
The composition for inhibiting prostatic hyperplasia comprises dried rhizome extract of Curcuma rhizome (Curcuma longa L.) belonging to Curcuma of Zingiberaceae, and curcumin as main chemical component. Curcuma rhizome has anti-tumor, antioxidant, liver protecting, blood sugar lowering, antiinflammatory, antibacterial, and antiviral effects. Curcumin compounds in Curcuma rhizome have effects of reducing inflammatory cytokine in prostate tissue, inhibiting prostate cancer cell proliferation, inhibiting 15-lipoxygenase (15-LOX), and inducing apoptosis of hormone-dependent prostate cancer cell LNCaP and hormone-independent prostate cancer cell PC 3. Meanwhile, curcumin can inhibit the proliferation of prostate interstitial cells and induce the prostate interstitial cells to generate apoptosis; lycopene is one of carotenoid, and has effects in resisting oxidation, scavenging free radicals, protecting cardiovascular and cerebrovascular system, and enhancing immunity; the mixed tocopherol is natural vitamin E extracted from oil, and has antioxidant, neuroprotective, antiinflammatory and cholesterol lowering effects.
The composition for inhibiting the prostatic hyperplasia is prepared by matching the turmeric, the lycopene and the mixed tocopherol, and the curcumin in the turmeric can inhibit inflammatory factors, can inhibit the proliferation of prostate interstitial cells and induce the prostate interstitial cells to undergo apoptosis, so that the wet weight of the prostate can be obviously reduced and the prostate index can be obviously reduced; lycopene reduces DNA damage, improves oxidative stress defense; the mixed tocopherol can promote blood circulation and balance hormone level in vivo. The increase of mixed tocopherol can further improve the inhibiting effect of the turmeric and the lycopene. The three functional raw materials are compounded to realize the synergistic effect of multiple ways to improve the prostatic hyperplasia. In addition, the three components are common food materials or food additives, and the composition has high safety.
Preferably, the composition for inhibiting the prostatic hyperplasia consists of the following components in parts by weight: 12.5-25 parts of turmeric, 12.5-50 parts of mixed tocopherol and 12.5-25 parts of lycopene. Under the condition of the components in parts by weight, the inhibition efficiency of the collocation of the components on the prostatic hyperplasia is obviously improved. The composition prepared at this specific ratio has the highest efficiency of inhibiting prostatic hyperplasia.
The invention also aims to provide a preparation method of the composition for inhibiting the prostatic hyperplasia.
The preparation method of the composition for inhibiting the prostatic hyperplasia comprises the step of uniformly mixing turmeric, mixed tocopherol and lycopene to obtain the composition for inhibiting the prostatic hyperplasia.
The preparation method of the composition for inhibiting the prostatic hyperplasia, which is provided by the invention, has simple preparation process and can be industrially produced in a large scale.
Meanwhile, the three components in the composition can be prepared and extracted according to actual conditions, can be directly purchased from the market, and can be replaced by raw materials, semi-finished products or added finished products with the same components without influencing the efficacy of the prepared product: the Curcuma rhizome can be prepared by extracting Curcuma rhizome, and refining; the mixed tocopherol can be replaced by one or a mixture of several tocopherols of different molecular formulas or compounds with similar structures; lycopene can be replaced by non-pure lycopene-rich substances extracted from plants, or by substances containing lycopene or structural analogs obtained by biological fermentation or chemical synthesis.
The invention also aims to provide the application of the composition for inhibiting the prostatic hyperplasia in the preparation of products for inhibiting the prostatic hyperplasia. The composition for inhibiting the prostatic hyperplasia has stable performance, can be processed into various dosage forms, and is suitable for processing and preparing products in various forms.
More preferably, the prostate hyperplasia-inhibiting product comprises a food, a health product or a medicament.
Preferably, the product for inhibiting the prostatic hyperplasia further comprises auxiliary materials, wherein the auxiliary materials comprise a flavoring agent, a thickening agent, a disintegrating agent and a filling agent. On the premise of not influencing the main components of the product for inhibiting the prostatic hyperplasia, the necessary auxiliary materials are added in the product to further enhance and provide the taste, the storage stability, the medicinal effect and the like of the product, and the person skilled in the art can select the common content according to the conventional standard.
Preferably, the dosage form of the prostate hyperplasia inhibition product comprises solid beverage, granules, capsules or tablets. The preparation form of the product can be adjusted according to the actual requirement on the premise of not influencing the component structure and the component stability of the composition.
The composition for inhibiting the prostatic hyperplasia has the beneficial effects that the turmeric, the lycopene and the mixed tocopherol are compounded, and the curcumin in the turmeric can inhibit inflammatory factors, can inhibit the proliferation of prostate interstitial cells and induce the prostate interstitial cells to undergo apoptosis; lycopene reduces DNA damage, improves oxidative stress defense; the mixed tocopherol can promote blood circulation and balance hormone level in vivo. Through the synergistic interaction of the components, the traditional Chinese medicine composition can effectively inhibit the prostatic hyperplasia, and has better effect compared with the effect of singly using the turmeric and the lycopene. In addition, the composition for inhibiting the prostatic hyperplasia has high safety and no toxic or side effect. The invention also provides a preparation method of the composition for inhibiting the prostatic hyperplasia, and the preparation method has simple preparation process and can be used for industrial mass production. The invention also provides application of the composition for inhibiting the prostatic hyperplasia in preparation of a product for inhibiting the prostatic hyperplasia.
Detailed Description
Unless otherwise specified, the raw materials used in the examples of the present invention and comparative examples were commercially available, and the production equipment used was a commercially available common model. The turmeric Ar juna Natural Extracts Ltd in the examples and comparative examples of the present invention is provided by production; the mixed tocopherols and lycopene are products produced by basf corporation.
For better illustrating the objects, technical solutions and advantages of the present invention, the present invention will be further described with reference to specific examples, which are intended to be understood in detail, but not intended to limit the present invention.
Example 1
One embodiment of the composition for inhibiting the prostatic hyperplasia comprises the following components in parts by weight: 12.5 parts of turmeric, 12.5 parts of mixed tocopherol and 12.5 parts of lycopene.
The preparation method of the composition for inhibiting prostatic hyperplasia comprises the following steps: and respectively sieving the turmeric, the mixed tocopherol and the lycopene, weighing according to the weight parts, uniformly mixing and subpackaging to obtain the product for inhibiting the prostatic hyperplasia.
Example 2
One embodiment of the composition for inhibiting the prostatic hyperplasia comprises the following components in parts by weight: 12.5 parts of turmeric, 25 parts of mixed tocopherol and 12.5 parts of lycopene.
The preparation of the composition for inhibiting prostatic hyperplasia described in this example is the same as in example 1.
Example 3
One embodiment of the composition for inhibiting the prostatic hyperplasia comprises the following components in parts by weight: 12.5 parts of turmeric, 50 parts of mixed tocopherol and 25 parts of lycopene.
The preparation of the composition for inhibiting prostatic hyperplasia described in this example is the same as in example 1.
Example 4
One embodiment of the composition for inhibiting the prostatic hyperplasia comprises the following components in parts by weight: 25 parts of turmeric, 12.5 parts of mixed tocopherol and 12.5 parts of lycopene.
The preparation of the composition for inhibiting prostatic hyperplasia described in this example is the same as in example 1.
Example 5
One embodiment of the composition for inhibiting the prostatic hyperplasia comprises the following components in parts by weight: 12.5 parts of turmeric, 25 parts of mixed tocopherol and 25 parts of lycopene; the composition is used for preparing a preparation for inhibiting the hyperplasia of prostate, and the preparation further comprises: 30 parts of flavoring agent, 40 parts of maltodextrin, 50 parts of microcrystalline cellulose, 305 parts of povidone K, 2 parts of silicon dioxide and 3 parts of magnesium stearate.
The preparation method of the product for inhibiting the prostatic hyperplasia comprises the following steps: weighing the components according to the corresponding weight parts, sieving, feeding into a mixing machine, uniformly mixing, granulating, tabletting and bottling to obtain the product for inhibiting the prostatic hyperplasia.
Example 6
One embodiment of the composition for inhibiting the prostatic hyperplasia comprises the following components in parts by weight: 12.5 parts of turmeric, 25 parts of mixed tocopherol and 12.5 parts of lycopene; the composition is used for preparing a preparation for inhibiting the hyperplasia of prostate, and the preparation further comprises: 4 parts of beeswax, 100 parts of gelatin, 50 parts of glycerol and 100 parts of purified water.
The preparation method of the product for inhibiting the prostatic hyperplasia comprises the following steps: mixing the raw materials according to a formula, homogenizing, melting gelatin, pressing pills, washing pills, drying, selecting pills, and packaging to obtain the soft capsule, namely the product for inhibiting the prostatic hyperplasia.
Comparative example 1
The comparative example differs from example 1 only in that the composition of the comparative example has the following components: 12.5 parts of turmeric.
Comparative example 2
The comparative example differs from example 1 only in that the composition of the comparative example has the following components: 25 parts of turmeric.
Comparative example 3
The comparative example differs from example 1 only in that the composition of the comparative example has the following components: mixed tocopherol of 12.5 parts and lycopene of 12.5 parts.
Comparative example 4
The comparative example differs from example 1 only in that the composition of the comparative example has the following components: mixed tocopherol 25 parts and lycopene 12.5 parts.
Comparative example 5
The comparative example differs from example 1 only in that the composition of the comparative example has the following components: 15 parts of mixed tocopherol, 0.5 part of tomato red, 15 parts of turmeric and 100 parts of rape pollen.
In order to verify the influence of the composition for inhibiting the prostatic hyperplasia, prepared in the examples 1-4 and the comparative examples 1-5, on the prostatic hyperplasia cells, the composition products are used for the BPH-1 cell culture test of the prostatic hyperplasia cells.
The test uses human benign prostatic hyperplasia BPH-1 cells derived from prostatic epithelial tissue of a patient with prostatic hyperplasia;
the cell suspension and the added reagent used in the test are: 1640 culture solution, trypsin, PBS buffer solution, tetramethyl azozolium (MTT) and dimethyl sulfoxide (DMSO);
the experimental instruments needed to be used in the test are as follows: the device comprises a 96-pore plate, a biological safety cabinet, a carbon dioxide incubator, an enzyme-labeling instrument and an inverted microscope;
the test comprises the following specific steps: digesting human benign prostatic hyperplasia cell BPH-1, preparing single cell suspension with culture solution, and adjusting cell density to 1x104And inoculating each cell/well into a 96-well plate, wherein each well is 200 mu L, placing the plate in an incubator at 37 ℃ under a 5% CO2 culture environment, incubating for 24h, and then attaching the plate to the wall, and treating the plate for 48h by using each test group with different concentration ratios, wherein the dosages of each component in each test group are shown in table 1. After treatment, the culture medium was removed from the culture wells, 20. mu.L of MTT solution (500mg MTT in 100ml PBS) was added to each well, incubation was continued for 4h, the culture was terminated, and the wells were carefully aspiratedCulture supernatant, which is to be centrifuged for suspension cells and then the culture supernatant in the wells is aspirated. Add 150. mu.L DMSO solution into each well, shake for 10min to fully melt the crystals. The absorbance of each well was measured on a microplate reader at 490nm, and the results are shown in table 2, where% cell proliferation ÷ component absorbance value ÷ blank control absorbance value × 100%.
TABLE 1
TABLE 2
Note: # is relative to the blank group and is relative to the turmeric group at equivalent concentration; & is a group of mixed tocopherols + lycopene at equivalent concentrations; (vii) a, # # # or & & indicates p < 0.001; a, # # or & & indicates p <0.01, extremely significant; # or & indicates p <0.05, significant; the smaller the p-value, the more significant the difference.
As can be seen from Table 2, the mixed tocopherol + lycopene group 1 has no significant difference compared with the blank control group, which indicates that the mixed tocopherol + lycopene group 1 has no inhibitory effect on prostate BPH-1 cells. The other groups have significance relative to the blank group, which shows that the turmeric and the mixed tocopherol and lycopene group 2 have the effect of improving the prostatic hyperplasia, but in the mixed tocopherol and lycopene group 2, the BPH-1 hyperplasia rate is 89.78%, the inhibition rate% is only 10.22%, and the inhibition rate effect on the prostatic hyperplasia is not good.
The inhibition rate of the test groups 1-4 on the prostatic hyperplasia is better than that of the comparative example 5. Meanwhile, the test group 1 has very significant difference compared with the mixed tocopherol and lycopene group with the same concentration, and the proliferation rate of the turmeric group with the same concentration to BPH-1 is also reduced; the test groups 2 and 4 have significant differences relative to the turmeric group and the mixed tocopherol and lycopene group under the same concentration, wherein the test group 4 has the best effect, the BPH-1 proliferation rate is only 46.26%, and the result shows that the product compounded by the turmeric, the lycopene and the mixed tocopherol has the effect of synergistically inhibiting the prostatic hyperplasia.
Finally, it should be noted that the above embodiments are only used for illustrating the technical solutions of the present invention and not for limiting the protection scope of the present invention, and although the present invention is described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that modifications or equivalent substitutions can be made on the technical solutions of the present invention without departing from the spirit and scope of the technical solutions of the present invention.
Claims (6)
1. A composition for inhibiting prostatic hyperplasia, which comprises the following components: turmeric, mixed tocopherols, and lycopene.
2. The composition for inhibiting prostatic hyperplasia according to claim 1, which consists of the following components in parts by weight: 12.5-25 parts of turmeric, 12.5-50 parts of mixed tocopherol and 12.5-25 parts of lycopene.
3. The method of preparing a composition for inhibiting prostatic hyperplasia according to any one of claims 1 to 2, wherein the method comprises: the composition for inhibiting prostatic hyperplasia is prepared by mixing Curcuma rhizome, mixed tocopherol and lycopene.
4. Use of the composition for inhibiting prostatic hyperplasia according to any one of claims 1-2 in the preparation of a product for inhibiting prostatic hyperplasia.
5. The use of the composition for inhibiting prostatic hyperplasia according to claim 4 in the preparation of a product for inhibiting prostatic hyperplasia, wherein the components of the product for inhibiting prostatic hyperplasia further comprise adjuvants, and the adjuvants comprise a flavoring agent, a thickening agent, a disintegrating agent and a filler.
6. The use of the composition for inhibiting prostatic hyperplasia according to claim 5 in the preparation of a product for inhibiting prostatic hyperplasia, wherein the dosage form of the product for inhibiting prostatic hyperplasia comprises solid beverage, granules, capsules or tablets.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011595868.2A CN112656915A (en) | 2020-12-28 | 2020-12-28 | Composition for inhibiting prostatic hyperplasia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011595868.2A CN112656915A (en) | 2020-12-28 | 2020-12-28 | Composition for inhibiting prostatic hyperplasia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112656915A true CN112656915A (en) | 2021-04-16 |
Family
ID=75411984
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011595868.2A Withdrawn CN112656915A (en) | 2020-12-28 | 2020-12-28 | Composition for inhibiting prostatic hyperplasia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112656915A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101642446A (en) * | 2009-09-14 | 2010-02-10 | 蔡晓东 | Lycopene soft capsule |
| CN104940824A (en) * | 2015-06-26 | 2015-09-30 | 湖南炎帝生物工程有限公司 | Antioxidant health food beneficial to male prostatitis and application of antioxidant health food |
| CN105748529A (en) * | 2016-04-25 | 2016-07-13 | 汤臣倍健股份有限公司 | Combination with effect of inhibiting benign prostatic hyperplasia and application thereof |
| CN106174526A (en) * | 2016-08-08 | 2016-12-07 | 湖北省金贝嘉天然农业股份有限公司 | A kind of selenium-enriched food of anti-prostatic hyperplasia |
| CN110898114A (en) * | 2019-10-28 | 2020-03-24 | 安徽大学 | A pharmaceutical composition for treating prostatic hyperplasia |
-
2020
- 2020-12-28 CN CN202011595868.2A patent/CN112656915A/en not_active Withdrawn
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101642446A (en) * | 2009-09-14 | 2010-02-10 | 蔡晓东 | Lycopene soft capsule |
| CN104940824A (en) * | 2015-06-26 | 2015-09-30 | 湖南炎帝生物工程有限公司 | Antioxidant health food beneficial to male prostatitis and application of antioxidant health food |
| CN105748529A (en) * | 2016-04-25 | 2016-07-13 | 汤臣倍健股份有限公司 | Combination with effect of inhibiting benign prostatic hyperplasia and application thereof |
| CN106174526A (en) * | 2016-08-08 | 2016-12-07 | 湖北省金贝嘉天然农业股份有限公司 | A kind of selenium-enriched food of anti-prostatic hyperplasia |
| CN110898114A (en) * | 2019-10-28 | 2020-03-24 | 安徽大学 | A pharmaceutical composition for treating prostatic hyperplasia |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113150867B (en) | Preparation method of ganoderma lucidum extract oil rich in ganoderma lucidum triterpenes | |
| US10624942B2 (en) | Composition for amelioration of peri- and post-menopausal symptoms and a process for producing the same | |
| CN102218049B (en) | Anti-ageing medicine or health care food composition and application | |
| Yang et al. | Determination of active compounds in raspberry leaf extracts and the effects of extract intake on mice | |
| CN109602756A (en) | A kind of sobering-up composition and the preparation method and application thereof | |
| CN107136504A (en) | A kind of oxidation resistant functional food | |
| CN108497498A (en) | A kind of functional food of relieving alcoholism and protecting liver and preparation method thereof | |
| EP3117834A1 (en) | A bone and joint protection composition and use thereof | |
| CN103007000A (en) | New medicine for treating burns and wounds and preparation method thereof | |
| CN102198195A (en) | Antioxidative medicinal composition | |
| CN112603982A (en) | Composition for inhibiting prostatic hyperplasia | |
| CN112656915A (en) | Composition for inhibiting prostatic hyperplasia | |
| CN109453267A (en) | Sobering-up composition and the preparation method and application thereof | |
| Hassan et al. | Wheat Grass (Triticum aestivum L.) Benefits Health in a Pandemic Scenario | |
| CN103006712A (en) | Bee product extract with functions of resisting oxidation and eliminating free radicals | |
| CN113262229B (en) | Application of orychophragmine D in preparation of anti-radiation injury medicine | |
| KR101491493B1 (en) | Anti-inflammatory pharmaceutical composition comprising tangerine pericarp and Psidium guajava extract | |
| CN105796764B (en) | Preparation method and application of negundo chastetree fruit total lignans | |
| CN105343140A (en) | Total Chinese ephedra root effective portion and preparation method and anticancer application thereof | |
| AU2019100737A4 (en) | Anti-Helicobacter Pylori Traditional Chinese Medicine composition and applications | |
| CN112715938A (en) | Composition for inhibiting prostatic hyperplasia | |
| CN113577220A (en) | Medicinal composition for inhibiting prostate cancer and application thereof | |
| CN112569337A (en) | Composition for inhibiting prostatic hyperplasia | |
| CN112674340A (en) | Application of composition in preparation of product for inhibiting prostate cancer | |
| CN112656913A (en) | Composition for inhibiting prostatic hyperplasia and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20210416 |